Trial · NCT00623623
Results by group50
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 50
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS. | Tenecteplase (Group A) | 116 | Participants | ||
| Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS. | Primary PCI (Group B) | 135 | Participants | ||
| Number of Patients With All Cause Mortality | Tenecteplase (Group A) | 43 | Participants | ||
| Number of Patients With All Cause Mortality | Primary PCI (Group B) | 42 | Participants | ||
| Number of Patients With Cardiac Mortality | Tenecteplase (Group A) | 31 | Participants | ||
| Number of Patients With Cardiac Mortality | Primary PCI (Group B) | 32 | Participants | ||
| Number of Patients With Cardiogenic Shock | Tenecteplase (Group A) | 41 | Participants | ||
| Number of Patients With Cardiogenic Shock | Primary PCI (Group B) | 56 | Participants | ||
| Number of Patients With Congestive Heart Failure (CHF) | Tenecteplase (Group A) | 57 | Participants | ||
| Number of Patients With Congestive Heart Failure (CHF) | Primary PCI (Group B) | 72 | Participants | ||
| Number of Patients With Recurrent Myocardial Infarction (Reinfarction) | Tenecteplase (Group A) | 23 | Participants | ||
| Number of Patients With Recurrent Myocardial Infarction (Reinfarction) | Primary PCI (Group B) | 21 | Participants | ||
| Number of Patients With Rehospitalisation for Cardiac Reasons | Tenecteplase (Group A) | 45 | Participants | ||
| Number of Patients With Rehospitalisation for Cardiac Reasons | Primary PCI (Group B) | 41 | Participants | ||
| Number of Patients With Rehospitalisation for Non-cardiac Reasons | Tenecteplase (Group A) | 19 | Participants | ||
| Number of Patients With Rehospitalisation for Non-cardiac Reasons | Primary PCI (Group B) | 11 | Participants | ||
| Number of Patients With Serious Repeat Target Vessel Revascularization | Tenecteplase (Group A) | 1 | Participants | ||
| Number of Patients With Serious Repeat Target Vessel Revascularization | Primary PCI (Group B) | 2 | Participants | ||
| Number of Patients With All Cause Death and Shock | Tenecteplase (Group A) | 59 | Participants | ||
| Number of Patients With All Cause Death and Shock | Primary PCI (Group B) | 73 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00623623/results